menu
    • menu
    [{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ BofA Securities"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"IL-10","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMT-101","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AMT-101","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Applied Molecular Transport \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Molecular Transport \/ Not Applicable"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Molecular Transport \/ Cyclo Therapeutics"},{"orgOrder":0,"company":"Applied Molecular Transport","sponsor":"Cyclo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Applied Molecular Transport","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Applied Molecular Transport \/ Cyclo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Applied Molecular Transport \/ Cyclo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Applied Molecular Transport

    Menu

    Applied Molecular Transport

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

                            Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

                            Brand Name : Trappsol Cyclo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 27, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

                            Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

                            Brand Name : Trappsol Cyclo

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 21, 2023

                            Lead Product(s) : Hydroxypropyl-Beta Cyclodextrin

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Cyclo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouch...

                            Details : AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis and RA

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 03, 2023

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 ...

                            Details : AMT-126 is a novel GI-selective, oral fusion of IL-22 and AMT’s proprietary carrier molecule for diseases related to intestinal epithelial (IE) barrier defects.

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 22, 2022

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchiti...

                            Details : AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in four Phase 2 clinical trials for chronic pouchitis, UC and RA.

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 10, 2022

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patie...

                            Details : AMT-101 is a novel GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule, currently in development in Phase 2 clinical trials for chronic pouchitis, UC and RA.

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101,Adalimumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 i...

                            Details : AMT-101 is a novel, GI-selective, investigational oral recombinant biologic fusion protein of human interleukin 10 (hIL-10), an anti-inflammatory cytokine, in development for the treatment of inflammatory bowel diseases and systemic inflammatory indicati...

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2022

                            Lead Product(s) : AMT-101,Adalimumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in...

                            Details : AMT-101, a GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule demonstrated favorable clinical activity and appeared safe and well-tolerated, supporting potentially best-in-class profile in FILLMORE monotherapy trial .

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 25, 2022

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021

                            Details : AMT-101 is a novel, GI-selective, investigational oral recombinant biologic fusion protein of human interleukin 10 (hIL-10), an anti-inflammatory cytokine, in development for the treatment of inflammatory bowel diseases and systemic inflammatory indicati...

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 11, 2021

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Applied Molecular Transport

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of AMT-101 for I...

                            Details : AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue.

                            Brand Name : AMT-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 10, 2020

                            Lead Product(s) : AMT-101

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth